Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Open Access Highly Accessed Research article

Exercise training in pulmonary arterial hypertension associated with connective tissue diseases

Ekkehard Grünig1*, Felicitas Maier1, Nicola Ehlken1, Christine Fischer2, Mona Lichtblau1, Norbert Blank3, Christoph Fiehn4, Frank Stöckl5, Felix Prange1, Gerd Staehler6, Frank Reichenberger7, Henning Tiede7, Michael Halank8, Hans-Jürgen Seyfarth9, Simone Wagner10 and Christian Nagel1

Author Affiliations

1 Centre for Pulmonary Hypertension at Thoraxclinic Heidelberg, Thoraxclinic at the University Hospital Heidelberg, Amalienstraße 5, Heidelberg, 69126, Germany

2 Department of Human Genetics, University of Heidelberg, Im Neuenheimer Feld 366, Heidelberg, 69120, Germany

3 Department of Rheumatology, University of Heidelberg, Im Neuenheimer Feld 410, Heidelberg, 69120, Gemany

4 Department of Rheumatology, ACURA Centre for Rheumatic Diseases, Rotenbachtalstraße 5, Baden-Baden, 76530, Germany

5 Department of Internal Medicine, Medical Clinic III, Grafenstraße 9, Darmstadt, 64283, Germany

6 Centre for Pulmonary Hypertension, Clinic Löwenstein, Geißhölzle 62, Löwenstein, 74245, Germany

7 Department of Pneumology, University Hospital Gießen, Klinikstraße 33, Giessen, 35392, Germany

8 Department of Pneumology, University Hospital Dresden, Fetscherstraße 74, Dresden, 01307, Germany

9 Department of Pneumology, University Hospital Leipzig, Liebigstraße 20, Leipzig, 04103, Germany

10 Department of Neurology, University Hospital Heidelberg, Im Neuenheimer Feld 400, Heidelberg, 69126, Germany

For all author emails, please log on.

Arthritis Research & Therapy 2012, 14:R148  doi:10.1186/ar3883

Published: 18 June 2012

Abstract

Introduction

The objective of this prospective study was to assess short- and long-term efficacy of exercise training (ET) as add-on to medical therapy in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-APAH).

Methods

Patients with invasively confirmed CTD-APAH received ET in-hospital for 3 weeks and continued at home for 12 weeks. Efficacy parameters have been evaluated at baseline and after 15 weeks by blinded-observers. Survival rate has been evaluated in a follow-up period of 2.9 ± 1.9 years.

Results

Twenty-one consecutive patients were included and assessed at baseline, and after 3 weeks, 14 after 15 weeks. Patients significantly improved the mean distance walked in 6 minutes compared to baseline by 67 ± 52 meters after 3 weeks (p < 0.001) and by 71 ± 35 meters after 15 weeks (p = 0.003), scores of quality of life (p < 0.05), heart rate at rest, peak oxygen consumption, oxygen saturation and maximal workload. Systolic pulmonary artery pressure and diastolic systemic blood pressure improved significantly after 3 weeks of ET. The 1- and 2-year overall-survival rates were 100%, the 3-year survival 73%. In one patient lung transplantation was performed 6 months after ET.

Conclusion

ET as add-on to medical therapy is highly effective in patients with CTD-APAH to improve work capacity, quality of life and further prognostic relevant parameters and possibly improves the 1-, 2- and 3-year survival rate. Further randomized controlled studies are needed to confirm these results.

Trial registration

ClinicalTrials.gov: NCT00491309.